OS Therapies Incorporated (OSTX)
NYSEAMERICAN: OSTX · Real-Time Price · USD
1.470
-0.100 (-6.37%)
At close: Apr 17, 2025, 4:00 PM
1.550
+0.080 (5.44%)
After-hours: Apr 17, 2025, 4:38 PM EDT

Company Description

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States.

Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers.

OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland.

OS Therapies Incorporated
OS Therapies logo
Country United States
Founded 2018
IPO Date Aug 1, 2024
Industry Biotechnology
Sector Healthcare
Employees 5
CEO Paul Romness

Contact Details

Address:
15825 Shady Grove Road, Suite 135
Rockville, Maryland 20850
United States
Phone 410-297-7793
Website ostherapies.com

Stock Details

Ticker Symbol OSTX
Exchange NYSEAMERICAN
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
IPO Price $4.00
CIK Code 0001795091
ISIN Number US68764Y2072
Employer ID 82-5118368
SIC Code 2834

Key Executives

Name Position
Paul A. Romness M.P.H. Founder, Chairman, President and Chief Executive Officer
Christopher P. Acevedo Chief Financial Officer
Dr. Robert G. Petit Ph.D. Chief Medical Officer and Chief Scientific Officer
Jack Doll Chief of Staff
Gerald E. Commissiong Chief Business Officer

Latest SEC Filings

Date Type Title
Apr 16, 2025 SCHEDULE 13G Filing
Apr 15, 2025 8-K Current Report
Apr 9, 2025 8-K Current Report
Apr 2, 2025 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 2, 2025 8-K Current Report
Mar 31, 2025 8-K Current Report
Mar 31, 2025 10-K Annual Report
Mar 12, 2025 SCHEDULE 13D/A Filing
Mar 10, 2025 UPLOAD Filing
Feb 28, 2025 SCHEDULE 13D/A Filing